A DARPin promotes faster onset of botulinum neurotoxin A1 action

Nat Commun. 2023 Dec 18;14(1):8317. doi: 10.1038/s41467-023-44102-4.

Abstract

In this study, we characterize Designed Ankyrin Repeat Proteins (DARPins) as investigative tools to probe botulinum neurotoxin A1 (BoNT/A1) structure and function. We identify DARPin-F5 that completely blocks SNAP25 substrate cleavage by BoNT/A1 in vitro. X-ray crystallography reveals that DARPin-F5 inhibits BoNT/A1 activity by interacting with a substrate-binding region between the α- and β-exosite. This DARPin does not block substrate cleavage of BoNT/A3, indicating that DARPin-F5 is a subtype-specific inhibitor. BoNT/A1 Glu-171 plays a critical role in the interaction with DARPin-F5 and its mutation to Asp, the residue found in BoNT/A3, results in a loss of inhibition of substrate cleavage. In contrast to the in vitro results, DARPin-F5 promotes faster substrate cleavage of BoNT/A1 in primary neurons and muscle tissue by increasing toxin translocation. Our findings could have important implications for the application of BoNT/A1 in therapeutic areas requiring faster onset of toxin action combined with long persistence.

MeSH terms

  • Botulinum Toxins*
  • Botulinum Toxins, Type A* / metabolism
  • Clostridium botulinum* / genetics
  • Designed Ankyrin Repeat Proteins

Substances

  • Botulinum Toxins
  • Designed Ankyrin Repeat Proteins
  • Botulinum Toxins, Type A